XTX Topco Ltd Invests $237,000 in Inhibrx Biosciences, Inc. (NASDAQ:INBX)

XTX Topco Ltd purchased a new stake in shares of Inhibrx Biosciences, Inc. (NASDAQ:INBX - Free Report) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 16,918 shares of the company's stock, valued at approximately $237,000. XTX Topco Ltd owned 0.12% of Inhibrx Biosciences as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of INBX. Bank of New York Mellon Corp grew its position in Inhibrx Biosciences by 2.6% during the first quarter. Bank of New York Mellon Corp now owns 52,800 shares of the company's stock worth $739,000 after buying an additional 1,355 shares in the last quarter. Natixis bought a new stake in shares of Inhibrx Biosciences during the 4th quarter valued at about $31,000. JPMorgan Chase & Co. grew its holdings in shares of Inhibrx Biosciences by 47.8% during the fourth quarter. JPMorgan Chase & Co. now owns 7,592 shares of the company's stock worth $117,000 after purchasing an additional 2,457 shares in the last quarter. State of Wyoming bought a new position in shares of Inhibrx Biosciences in the fourth quarter worth approximately $83,000. Finally, Corebridge Financial Inc. purchased a new stake in Inhibrx Biosciences in the fourth quarter valued at approximately $89,000. 82.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Wall Street Zen raised shares of Inhibrx Biosciences from a "sell" rating to a "hold" rating in a research note on Sunday. JMP Securities reissued a "market perform" rating on shares of Inhibrx Biosciences in a research note on Thursday, May 15th.

Inhibrx Biosciences Price Performance

INBX traded down $0.61 during midday trading on Friday, hitting $23.33. The stock had a trading volume of 97,771 shares, compared to its average volume of 106,741. Inhibrx Biosciences, Inc. has a 1 year low of $10.81 and a 1 year high of $25.29. The company has a debt-to-equity ratio of 1.45, a quick ratio of 5.12 and a current ratio of 4.98. The business has a fifty day moving average of $19.36 and a 200 day moving average of $15.11. The company has a market cap of $337.94 million, a P/E ratio of -2.21 and a beta of 0.24.

Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($1.85) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.92) by $1.07. The business had revenue of $1.30 million during the quarter. As a group, equities analysts forecast that Inhibrx Biosciences, Inc. will post 104.88 earnings per share for the current fiscal year.

Inhibrx Biosciences Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.